Primary Management of Localized Gastrointestinal Stromal Tumors With Imatinib Monotherapy: An Alternative to Resection of Patients Precluded From Surgery
Patients tolerated imatinib monotherapy well and demonstrated robust survival data. Our research highlights a new potential application for imatinib in a patient population that has historically been precluded from standard-of-care therapy for their disease.
Authors
- Jeffrey D. Wayne (ORCID: https://orcid.org/0000-0002-9934-1109)
- Vinai Gondi
- Seth M. Pollack (ORCID: https://orcid.org/0000-0002-2466-0607)
- Farres Obeidin (ORCID: https://orcid.org/0000-0001-8461-9238)
- Brandon L Ellsworth
- John S. Wang (ORCID: https://orcid.org/0000-0001-5532-2101)
- Fahad Faruqi
- Borislav A. Alexiev (ORCID: https://orcid.org/0000-0002-0262-2263)
- John P. Hayes (ORCID: https://orcid.org/0000-0002-6462-6876)
- Rusul Al-Marayaty
- Pedro Hermida de Viveiros
- Akhil Chawla
- Sean Stencel
Institutions
- Northwestern University (US)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1177/11795549251346653
- Citations
- 2
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.62